A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
DRUG: ABP 234|DRUG: Pembrolizumab (US)|DRUG: Pembrolizumab (EU)
Objective response (OR), OR defined as an overall response of confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1., Week 49|Area under the serum concentration-time curve (AUC) from time 0 to 21 days (AUC21d) of ABP 234, 21 days|AUC at steady state between Week 16 and Week 19 (AUCtau_ss) of ABP 234, Week 16 through Week 19
OR, Week 13|OR, Week 31|Duration of response (DOR), Up to 2.5 years|Progression-free survival (PFS), Up to 2.5 years|Overall survival (OS), Up to 2.5 years|Maximum observed serum concentration following the first dose (Cmax_dose1) of ABP 234, Day 1 up to Week 107|Cmax_dose1 of pembrolizumab (US), Day 1 up to Week 107|Cmax_dose1 of pembrolizumab (EU), Day 1 up to Week 107|Time to maximum concentration following the first dose (tmax_dose1) of ABP 234, Day 1 up to Week 107|Tmax_dose1 of pembrolizumab (US), Day 1 up to Week 107|Tmax_dose1 of pembrolizumab (EU), Day 1 up to Week 107|Maximum observed serum concentration (Cmax) at steady state (Cmax_ss) of ABP 234, Week 16 through Week 19|Cmax_ss of pembrolizumab (US), Week 16 through Week 19|Cmax_ss of of pembrolizumab (EU), Week 16 through Week 19|Time to maximum concentration at steady state (tmax_ss) of ABP 234, Week 16 through Week 19|Tmax_ss of pembrolizumab (US), Week 16 through Week 19|Tmax_ss of pembrolizumab (EU), Week 16 through Week 19|Trough serum concentrations at pre-dose of week 4 (Ctrough_w4) of ABP 234, Week 4|Ctrough_w4 of pembrolizumab (US), Week 4|Ctrough_w4 of pembrolizumab (EU), Week 4|Trough serum concentrations at steady state (Ctrough_ss) at pre-dose of ABP 234, Week 16 through Week 19|Ctrough_ss at pre-dose of pembrolizumab (US), Week 16 through Week 19|Ctrough_ss at pre-dose of pembrolizumab (EU), Week 16 through Week 19|AUC21d of pembrolizumab (US), 21 days|AUC21d of pembrolizumab (EU), 21 days|AUCtau_ss of pembrolizumab (US), Week 16 through Week 19|AUCtau_ss pembrolizumab (EU), Week 16 through Week 19|Number of participants who experience a Treatment-emergent adverse event, Up to 2.5 years|Number of participants who experience a Treatment-emergent serious adverse event, Up to 2.5 years|Number of participants who experience a Treatment-emergent adverse event of interest, Up to 2.5 years|Number of participants who experience anti-drug antibodies (ADA), Up to 2.5 years
The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).